Article Sidebar
Views pdf: 25
ASSESSMENT OF CLINICAL CHARACTERISTICS AND INITIAL 131I TREATMENT RESPONSE IN POST TOTAL THYROIDECTOMY PAPILLARY THYROID MIROCARCINOMA AND CONVENTIONAL PAPILLARY THYROID CARCINOMA
Main Article Content
Abstract
Objective: Comparison of clinical characteristics and initial 131I therapy response in post-total thyroidectomy papillary microcarcinoma and conventional papillary thyroid carcinoma (primary tumor size greater than 10 mm). Subject and Method: The retrospective and comparative study was conducted on 361 post-total thyroidectomy and initial 131I therapy of papillary thyroid carcinoma patients (232 papillary thyroid microcarcinoma) at the 108 Military Central Hospital. Clinical, histopathological characteristics, risk of recurrence, and initial 131I therapy response were evaluated in these patients. Results: In 232 out of 361 patients (64.3%) with papillary thyroid carcinoma (PTC), 87.1% were females, and 76.3% were under 55. The primary tumors predominantly exhibited multifocal and bilateral involvement. In 75.4% of papillary thyroid carcinoma with capsule invasion, 11.2% with extrathyroidal extension. 22.8% of PTC were observed with lymph node metastases, and 0.4% with distant metastasis. The rates of extrathyroidal extension and lymph node metastases were significantly lower in papillary thyroid microcarcinoma compared to conventional papillary thyroid carcinoma but rate of distant metastasis. The intermediate to high recurrence risk rates were significantly lower in papillary thyroid microcarcinoma. Initial 131I therapy response was significantly correlated with postoperative recurrence risk stratification in conventional papillary thyroid carcinoma. Conclusion: Papillary thyroid microcarcinoma accounts for 64.3% of PTCs. The capsule invasion and lymph node metastasis rates were significantly lower in papillary thyroid microcarcinoma compared to conventional papillary thyroid carcinoma. 66% of papillary thyroid microcarcinoma achieved complete response with initial 131I remnant ablation therapy. The initial 131I therapy response correlated with post-operative recurrence risk stratification in conventional papillary thyroid carcinoma.
Article Details
Keywords
papillary thyroid microcarcinoma, recurrence risk stratification, initial 131I therapy response, thyroid remnant ablation
References
2. Karatzas, T., et al., Risk factors contributing to the difference in prognosis for papillary versus micropapillary thyroid carcinoma. The American Journal of Surgery, 2013. 206(4): p. 586-593.
3. Qu, N., et al., Number of tumor foci predicts prognosis in papillary thyroid cancer. BMC Cancer, 2014. 14: p. 914.
4. So, Y.K., et al., Subclinical lymph node metastasis in papillary thyroid microcarcinoma: a study of 551 resections. Surgery, 2010. 148 (3): p. 526-531.
5. Kwak, J.Y., et al., Extrathyroid extension of well-differentiated papillary thyroid microcarcinoma on US. Thyroid, 2008. 18(6): p. 609-614.
6. Siddiqui, S., et al., Clinical and pathologic predictors of lymph node metastasis and recurrence in papillary thyroid microcarcinoma. Thyroid, 2016. 26(6): p. 807-815.
7. Jeon, M.J., et al., Features predictive of distant metastasis in papillary thyroid microcarcinomas. Thyroid, 2016. 26(1): p. 161-168.
8. Bal, C., et al., Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer, 1996. 77(12): p. 2574-80.